When Methotrexate Fails in Rheumatoid Arthritis with High RF/ACPA and Poor Prognostic Factors
This protocol applies to patients with rheumatoid arthritis who have no contraindication or early intolerance to methotrexate, have significant poor prognostic features — including elevated Rheumatoid Factor (RF) and/or ACPA — and have not achieved the treatment target on the initial csDMARD-based strategy.
Clinical Scenario — Poor Prognostic Factors Present
One or more of the following poor prognostic features are present in this patient:
- Positive Rheumatoid Factor (RF) and/or anti-citrullinated protein antibodies (ACPA), especially at high levels
- Persistently moderate or high disease activity despite csDMARD therapy
- High swollen joint count
- High acute phase reactant levels
- Presence of early erosions
- Failure of 2 or more csDMARDs
Previous Treatment — Target Not Achieved
The prior strategy — methotrexate with folic acid supplementation, combined with short-term glucocorticoids — did not reach the required treatment targets:
- At least 50% improvement in disease activity within 3 months
- Sustained remission (ACR-EULAR Boolean: swollen joint count ≤1, tender joint count ≤1, CRP ≤1 mg/dL, patient global assessment ≤2 cm on 10 cm VAS) or low disease activity by 6 months
Next-Line Approach (Partial Overview)
When poor prognostic factors are present and the initial csDMARD strategy has not achieved the target, the evidence-based approach involves adding a biologic DMARD (bDMARD) in combination with the existing csDMARD. Alternatively, a targeted synthetic DMARD (JAK inhibitor) may be considered following assessment of relevant individual risk factors. The complete structured regimen — including agent selection, sequencing, and monitoring intervals — is available in the full protocol.
Treatment Targets
The goal is at least 50% improvement in disease activity by 3 months, and sustained remission or low disease activity by 6 months. If either milestone is not met on schedule, the regimen should be adjusted accordingly.
References
DOI: 10.1136/ard-2022-223356
- MTX should be part of the first treatment strategy.
- In patients with a contraindication to MTX (or early intolerance), leflunomide or sulfasalazine should be considered as part of the (first) treatment strategy.
- If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present, a bDMARD should be added; JAK-inhibitors may be considered, but pertinent risk factors must be taken into account.
- Presence of RF and/or ACPA, especially at high levels
- Presence of early erosions
- Failure of 2 or more csDMARDs
- bDMARDs and tsDMARDs should be combined with a csDMARD; in patients who cannot use csDMARDs as comedication, IL-6 pathway inhibitors and tsDMARDs may have some advantages compared with other bDMARDs.
- Treatment should be aimed at reaching a target of sustained remission or low disease activity in every patient.
- Monitoring should be frequent in active disease (every 1-3 months); if there is no improvement by at most 3 months after the start of treatment or the target has not been reached by 6 months, therapy should be adjusted.
- ACR and EULAR have endorsed an increase of the PGA threshold in the Boolean definition of remission from 1 to 2 cm on a 10 cm VAS, while continuing to keep swollen and tender joints at a maximum of 1 and C reactive protein (CRP) at a maximum of 1 mg/dL.
View source ↗